REG - Arecor Therapeutics - Arecor granted key patents in Europe and China

Arecor TherapeuticsAnnouncement

27/06/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230627:nRSa9686Da&default-theme=true

RNS Number : 9686D  Arecor Therapeutics PLC  27 June 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR GRANTED KEY PATENTS IN EUROPE AND CHINA TO PROTECT PROPRIETARY INSULIN
PRODUCTS

 

Patents further strengthen Group's extensive patent portfolio protecting its
Arestat™ technology and innovative insulin products, AT278 and AT247

 

Cambridge, UK, 27 June 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
is pleased to announce that the European Patent Office has granted a key
patent (EP3518892), protecting novel formulations of the Group's proprietary
insulin products, AT278 and AT247. In addition, the China National
Intellectual Property Administration has granted a further patent
(CN110582285) protecting AT278 and AT247.

 

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "Our innovative
Arestat™ enabled insulin products, AT278 and AT247, have the potential to
address key needs in the better treatment of diabetes. AT278 is a 'disrupter
insulin', a unique formulation which combines an ultra-rapid profile and high
concentration and has potential as the gold standard insulin for the growing
population of people with high daily insulin needs, as well as a key enabler
for pump miniaturisation and extended wear-time. AT247 has a 'best-in-class'
ultra-rapid pharmacokinetic profile with the potential to enable fully
automated insulin delivery systems.  Diabetes is one of the leading causes of
death and disability worldwide, and affects people regardless of country, age
group, or sex. These additional granted patents aim to serve and protect
Arecor's innovative technologies in these important markets."

 

Arecor has invested in a strong patent portfolio to protect the Arestat™
technology platform and its proprietary pipeline products. The Group's
intellectual property (IP) portfolio currently comprises 36 patent families,
including >75 granted patents in Europe, the US and in other key
territories, and provides protection for its key products.  As part of this
strategy, Arecor has robust IP that protects the novel compositions of AT278
and AT247 as well as their specific properties and methods of use until 2037.

 

AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that
has been designed to accelerate the absorption of insulin post injection, even
when delivered at a high concentration. It has the potential to enable more
effective management of blood glucose levels, especially in people with high
daily insulin needs, whilst maintaining the convenience and compliance
benefits that come from a lower injection volume via a single injection.
Moreover, a truly rapid acting concentrated insulin is also a critical step
towards developing the next generation of miniaturised insulin patch pumps, as
well as pumps with longer wear-time and that can serve people with diabetes
with a broader range of daily insulin needs.

 

AT247 is an ultra-rapid insulin that has been demonstrated in Phase I clinical
studies to significantly accelerate insulin absorption. The faster absorption
enables a more effective management of blood glucose levels for people living
with diabetes, allowing for dosing closer to mealtimes.  Faster acting
insulins, in combination with state-of-the-art insulin pumps, glucose sensors
and treatment algorithms are all necessary components of an  'artificial
pancreas' designed to more closely mimic natural insulin function.

 

-ENDS-

 

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBGDLBGDDGXL